NPS Pharma Reveals New Data From STEPS 2 Support Long Term Use Of Gattex

(RTTNews) - NPS Pharmaceuticals, Inc. (NPSP reported new findings from STEPS 2 trial, supporting the long-term use of Gattex for injection in adult patients with Short Bowel Syndrome or SBS. Gattex is indicated for Short Bowel Syndrome who are dependent on parenteral support in the U.S.

STEPS 2 is a two-year open-label extension study of 88 adult patients with SBS. Investigators reported that the long-term use of Gattex in patients with SBS led to additional, clinically meaningful reductions in the volume and days per week of parenteral support requirements in this extension trial. Further, 10 of the 13 patients who achieved complete independence from parenteral support were those who received 30 months of Gattex in the 6-month STEPS pivotal study and the 24-month STEPS 2 study.

STEPS 2's primary objective was to study long-term safety and durability of effect in patients who completed, participated in, or qualified for participation in STEPS, a 24-week, placebo-controlled, multi-center, international Phase 3 study of Gattex in adult subjects with SBS.